Silence Therapeutics PLC 10-Q quarterly reports

Silence Therapeutics plc filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and outlining the need for future capital raises.

Silence Therapeutics plc reported a net loss of $14.96 million for Q1 2026, with a significant decrease in R&D costs and a cash runway extending into 2028.

Silence Therapeutics plc reported increased net losses and decreased revenue for Q3 2025, while advancing its Divesiran and Zerlasiran clinical programs and navigating collaboration changes.

Silence Therapeutics plc reported a significant increase in net loss and a sharp decline in revenue for Q2 2025, while advancing key clinical programs and pausing another.

Silence Therapeutics reports a net loss of $28.53 million for Q1 2025, with a focus on advancing clinical trials and seeking partnerships.